zig-zag,Inc.
340A
TOYOKOH Inc.
341A
PROGRESS TECHNOLOGIES GROUP,Inc.
339A
ZenmuTech
338A
Dynamic Map Platform Co.,Ltd.
336A
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.